Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Table 1 Baseline soluble protein levels and ratios to baseline in patients stratified by clinical response (RECIST and Choi criteria)

Soluble protein and time point	RECIST					Choi criteria
	Disease control		No disease control		Rank sum P -value	Responders		Non-responders		Rank sum P -value
	Median	n	Median	n		Median	n	Median	n
VEGF-A
Baseline, pg/mL	108.7	14	46.6	13	0.0332*	92.7	17	51.9	9	0.0250*
C2D1:D1	0.861	14	1.132	8	0.0352*	0.861	14	1.105	6	0.0757
C2D28:D1	1.426	13	3.617	6	0.0874	1.639	12	3.63	3	0.5363
VEGF-C
Baseline, pg/mL	1,416.5	14	741.5	13	0.0027*	1058	17	774.8	9	0.0662
C1D28:D1	0.529	13	0.806	9	0.0708	0.595	15	1.121	7	0.0319*
C2D1:D1	0.596	14	0.947	8	0.0197*	0.5636	14	0.839	6	0.0256*
sVEGFR-3
C1D14:D1	0.352	14	0.622	12	0.031*	0.4857	17	0.613	9	0.4580

Disease control (RECIST) defined as complete or partial response or stable disease > 12 weeks; no disease control defined as stable disease < 12 weeks or progressive disease
*Significant at the 0.05 level
C, cycle; D, day

ISSN: 1479-5876